Analysis of Gene Expression Profiles in an Imatinib‐Resistant Cell Line, KCL22/SR
Open Access
- 1 May 2003
- journal article
- research article
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 21 (3) , 315-321
Abstract
The BCR/ABL tyrosine kinase inhibitor, imatinib, has shown substantial effects in blast crises of chronic myelogenous leukemia. However, most patients relapse after an initial clinical response, indicating that drug resistance is a major problem for patients being treated with imatinib. In this study, we generated a new imatinib‐resistant BCR/ABL‐positive cell line, KCL22/SR. The 50% inhibitory concentration of imatinib was 11‐fold higher in KCL22/SR than in the imatinib‐sensitive parental cell line, KCL22. However, KCL22/SR showed no mutations in the BCR/ABL gene and no increase in the levels of BCR/ABL protein and P‐glycoprotein. Furthermore, the level of phosphorylated BCR/ABL protein was suppressed by imatinib treatment, suggesting that mechanisms independent of BCR/ABL signaling are involved in the imatinib resistance in KCL22/SR cells. DNA microarray analyses demonstrated that the signal transduction‐related molecules, RAS p21 protein activator and RhoA, which could affect Ras signaling, and a surface tumor antigen, L6, were upregulated, while c‐Myb and activin A receptor were downregulated in KCL22/SR cells. Furthermore, imatinib treatment significantly suppressed the level of phosphorylated p44/42 in KCL22 cells but not in KCL22/SR cells, even when BCR/ABL was inhibited by imatinib. These results suggest that various mechanisms, including disturbance of Ras‐mitogen‐activated protein kinase signaling, are involved in imatinib resistance.Keywords
This publication has 23 references indexed in Scilit:
- Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cellsOncogene, 2001
- Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemiaLeukemia, 2001
- Imatinib mesylate: Clinical results in Philadelphia chromosome-positive leukemiasSeminars in Oncology, 2001
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Cross‐talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motilityThe EMBO Journal, 2001
- Signaling from Rho to the Actin Cytoskeleton Through Protein Kinases ROCK and LIM-kinaseScience, 1999
- Molecular Cloning of Two Types of GAP Complementary DNA from Human PlacentaScience, 1988
- Establishment of a Ph 1 chromosome‐positive cell line from chronic myelogenous leukemia in blast crisisStem Cells, 1983